MBX Biosciences (MBX) Total Non-Current Liabilities (2023 - 2026)

MBX Biosciences has disclosed Total Non-Current Liabilities across 4 years of filings, most recently posting $14.9 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $14.9 million, up 42.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.9 million (up 42.58% YoY), and the FY2025 annual result was $15.9 million, up 44.05% from the prior year.
• Total Non-Current Liabilities came in at $14.9 million for Q1 2026 at MBX Biosciences, down from $15.9 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $15.9 million in Q4 2025 to a low of $4.1 million in Q4 2023.
• The 4-year median for Total Non-Current Liabilities is $11.7 million (2024), against an average of $11.5 million.
• Across the five-year window, Total Non-Current Liabilities surged 169.73% in 2024 and advanced 14.29% in 2025, its largest moves.
• MBX Biosciences' Total Non-Current Liabilities stood at $4.1 million in 2023, then jumped by 169.73% to $11.1 million in 2024, then soared by 44.05% to $15.9 million in 2025, then dropped by 6.12% to $14.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $14.9 million (Q1 2026), $15.9 million (Q4 2025), and $12.5 million (Q3 2025), per Business Quant data.